Mediar Therapeutics Enters into a Collaboration and Option Agreement with Ono Pharma to Develop Novel Treatments for Fibro-inflammatory Diseases August 6, 2026
Mediar Therapeutics Announces First Cohorts Dosed in Phase 1 Clinical Trial of MTX-439 for Fibrosis Associated with Chronic Kidney Disease (CKD) and Additions to Clinical Advisory Board June 24, 2026
Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio January 7, 2026
